• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Aditxt Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    4/17/25 4:45:57 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADTX alert in real time by email
    false 0001726711 0001726711 2025-04-17 2025-04-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): April 17, 2025

     

    ADITXT, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-39336   85-3204328
    (State or other jurisdiction of incorporation)   (Commission File Number)

     

     

    (I.R.S. Employer Identification No.)

     

    2569 Wyandotte Street, Suite 101, Mountain View, CA 94043

    (Address of principal executive offices, including ZIP code)

     

    (650) 870-1200

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425 )

     

    ☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001   ADTX   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    On April 17, 2025, Aditxt, Inc. (the “Company”) reconvened the special meeting of stockholders (the “Reconvened Special Meeting”), which was initially held on February 28, 2025 in virtual format and adjourned until March 17, 2025 and subsequently adjourned on March 17, 2025 until April 17, allowing additional time for stockholders to vote on the following proposals: (i) to approve, for the purpose of Nasdaq Marketplace Rule 5635(d), the issuance of shares of common stock underlying shares of Series A-1 Convertible Preferred Stock originally issued by the Company in December 2023 (Proposal 1); (ii) to approve, for the purpose of Nasdaq Marketplace Rule 5635(d), the issuance of shares of common stock underlying shares of Series C-1 Convertible Preferred Stock and common stock purchase warrants originally issued by the Company in May 2024 and August 2024 (Proposal 2); and (iii) to approve, for the purpose of Nasdaq Marketplace Rule 5635(d), the issuance of shares of common stock underlying common stock purchase warrants originally issued by the Company in July 2024 (Proposal 3). An aggregate of 28,636,023 shares of the Company’s common stock or approximately 36.17% of the voting authority, constituting a quorum, were represented virtually, in person, or by valid proxies at the Special Meeting..

     

    The final results for each of the matters (Proposals 1, 2 and 3) submitted to a vote of stockholders at the Reconvened Special Meeting, as set forth in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on January 27, 2025, are as follows:

     

    Proposal 1. At the Reconvened Special Meeting, the proposal to approve, for the purpose of Nasdaq Marketplace Rule 5635(d), the issuance of shares of common stock underlying shares of Series A-1 Convertible Preferred Stock originally issued by the Company in December 2023. During the Reconvened Special Meeting, Proposal 1 did not pass as it did not receive the affirmative vote of the holders of a majority in voting power of the votes cast. The result of the votes for Proposal 1 were as follows:

     

    For   Against   Abstain   Broker Non-Vote
    4,504,460   4,927,835   747,635   18,356,093

     

    Proposal 2. At the Reconvened Special Meeting, the proposal to approve, for the purpose of Nasdaq Marketplace Rule 5635(d), the issuance of shares of common stock underlying shares of Series C-1 Convertible Preferred Stock and common stock purchase warrants originally issued by the Company in May 2024 and August 2024. During the Reconvened Special Meeting, Proposal 2 did not pass as it did not receive the affirmative vote of the holders of a majority in voting power of the votes cast. The result of the votes for Proposal 2 were as follows:

     

    For   Against   Abstain   Broker Non-Vote
    4,482,280   4,928,198   769,452   18,356,093

     

     Proposal 3. At the Reconvened Special Meeting, the proposal to approve, for the purpose of Nasdaq Marketplace Rule 5635(d), the issuance of shares of common stock underlying common stock purchase warrants originally issued by the Company in July 2024. During the Reconvened Special Meeting, Proposal 3 did not pass as it did not receive the affirmative vote of the holders of a majority in voting power of the votes cast. The result of the votes for Proposal 3 were as follows:

     

    For   Against   Abstain   Broker Non-Vote
    4,512,470   4,906,295   761,165   18,356,093

     

     

      

    SIGNATURE

     

    Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    Dated: April 17, 2025

     

      Aditxt, Inc.
         
      By: /s/ Amro Albanna
      Name: Amro Albanna
      Title: Chief Executive Officer

     

    Get the next $ADTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADTX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ADTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Hrt Financial Lp bought $23,454 worth of Class A Shares (15,636 units at $1.50) and sold $29,875 worth of Class A Shares (25,534 units at $1.17), closing all direct ownership in the company (SEC Form 4)

      4 - Aditxt, Inc. (0001726711) (Issuer)

      10/17/24 1:58:54 PM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dawson James initiated coverage on ADiTx Therapeutics

      Dawson James initiated coverage of ADiTx Therapeutics with a rating of Buy

      2/4/21 8:32:09 AM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

      Event Begins Today at 11:30 a.m. ET Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Aditxt's CIO Dr. Shahrokh Shabahang, and Adimune's Co-CEO Dr. Friedrich Kapp, will join today's Aditxt Weekly Update to discuss recent developments related to ADI-100™, the lead therapeutic candidate of its wholly owned subsidiary, Adimune. Event Details: Title: Aditxt Weekly Update Date: Friday, May 2, 2025 Time: 11:30 a.m. ET Location: Virtual (Zoom) Registration: Click here to register About Adimune Adimune is a pre-clinical stage biopharmaceutical company pioneering a new class of immune modulation therapie

      5/2/25 9:00:00 AM ET
      $ADTX
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

      Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Dr. Charles Howe, Chair of the Division of Experimental Neurology and Director of Research at the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, will join the Aditxt Weekly Update on May 2, 2025, to discuss key findings from the newly announced preclinical study evaluating ADI-100™, the lead therapeutic candidate developed by its wholly owned subsidiary, Adimune™, Inc. ("Adimune"). Featured participants will include Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt, Inc., and Dr. Friedrich Kapp, Co-Chief Executive Offic

      4/17/25 8:15:00 AM ET
      $ADTX
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

      Prospective study to evaluate diagnostic performance and generate real-world data for the Mitomic® Endometriosis Test, a potential non-invasive approach to surgical diagnosis for endometriosis Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has received Institutional Review Board (IRB) approval from WCG Clinical to initiate a prospective clinical study evaluating the Mitomic® Endometriosis Test (MET), a novel blood-based diagnostic designed to aid in the early detection of endometriosis. The study, "Mitochondrial DNA Deletions in Plasma as a D

      4/16/25 8:15:00 AM ET
      $ADTX
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Hrt Financial Lp bought $23,454 worth of Class A Shares (15,636 units at $1.50) and sold $29,875 worth of Class A Shares (25,534 units at $1.17), closing all direct ownership in the company (SEC Form 4)

      4 - Aditxt, Inc. (0001726711) (Issuer)

      10/17/24 1:58:54 PM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Hrt Financial Lp claimed ownership of 25,434 units of Class A Shares (SEC Form 3)

      3 - Aditxt, Inc. (0001726711) (Issuer)

      10/17/24 1:31:48 PM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Pankovcin Corinne

      4 - Aditxt, Inc. (0001726711) (Issuer)

      11/13/23 4:30:12 PM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

      Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Dr. Charles Howe, Chair of the Division of Experimental Neurology and Director of Research at the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, will join the Aditxt Weekly Update on May 2, 2025, to discuss key findings from the newly announced preclinical study evaluating ADI-100™, the lead therapeutic candidate developed by its wholly owned subsidiary, Adimune™, Inc. ("Adimune"). Featured participants will include Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt, Inc., and Dr. Friedrich Kapp, Co-Chief Executive Offic

      4/17/25 8:15:00 AM ET
      $ADTX
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025

      Event exploring the escalating threat of emerging infectious diseases Discussion covering going-private transaction with Aditxt, strategic growth partner HALIFAX, Nova Scotia, April 02, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI, OTC:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that its President and CEO, Don Cilla, Pharm.D., M.B.A., will join Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt") Co-founder and CEO, Amro Albanna, for the Aditxt Weekly Update on April 4, 2025. The discussion will cover the Company's recent operational highlights, including $117 million in

      4/2/25 8:17:20 AM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update

      Four new funding proposals, totalling US$117.5 million, have been submitted for reviewModifications received to U.S. Air Force Academy Cooperative AgreementOutside date for going-private transaction extended to March 31, 2025 HALIFAX, Nova Scotia, March 18, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI, OTC:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that, the Company along with its partners, have submitted applications for four new federal funding opportunities. The funding, if awarded, would total up to US$117.5 million and support the company's

      3/18/25 7:22:22 AM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADTX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Aditxt Inc.

      10-Q - Aditxt, Inc. (0001726711) (Filer)

      5/15/25 4:36:46 PM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aditxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Aditxt, Inc. (0001726711) (Filer)

      5/15/25 4:05:09 PM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aditxt Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Aditxt, Inc. (0001726711) (Filer)

      5/5/25 4:15:26 PM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADTX
    Financials

    Live finance-specific insights

    See more
    • Evofem Reports Fourth Consecutive Year of Net Sales Growth

      -- 2024 Net Sales Increased 6% to $19.4 Million -- -- Total Operating Expense Reduced 27% from 2023 Levels, Excluding Non-cash Amortization Expense -- -- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch -- SAN DIEGO, March 24, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:E

      3/24/25 8:30:00 AM ET
      $ADTX
      $EVFM
      $WINT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

      — Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged commercial agreement for Phexxi in Middle East — SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the third quarter and nine-month period ended September 30, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences,

      11/14/24 4:36:00 PM ET
      $ADTX
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evofem Biosciences Announces Financial Results for the Second Quarter of 2024

      — Improved loss from operations by 81% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged ex-U.S. commercial agreement for Phexxi in Middle East — SAN DIEGO, Aug. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the second quarter and first half of 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">

      8/14/24 7:00:00 AM ET
      $ADTX
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Aditxt Inc. (Amendment)

      SC 13G/A - Aditxt, Inc. (0001726711) (Subject)

      2/14/24 2:14:47 PM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aditxt Inc. (Amendment)

      SC 13G/A - Aditxt, Inc. (0001726711) (Subject)

      2/6/24 10:06:47 AM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aditxt Inc. (Amendment)

      SC 13G/A - Aditxt, Inc. (0001726711) (Subject)

      1/2/24 3:10:18 PM ET
      $ADTX
      Biotechnology: Pharmaceutical Preparations
      Health Care